MedTrace Logo

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

NCT03582098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2019-04-12

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting

Conditions

Interventions

DRUG

Idelalisib

Tablets were administered in accordance with the marketing authorization.

DRUG

Rituximab

Tablets were administered in accordance with the marketing authorization.

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-12
Primary Completion
2019-03-26
Completion
2019-03-26

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03582098 on ClinicalTrials.gov